We are live on ! Find out more
SC

Sophrosyne Capital Portfolio holdings

AUM $11.5M
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
+10.95%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
+$7K
Cap. Flow
-$8.9M
Cap. Flow %
-7.79%
Top 10 Hldgs %
52.99%
Holding
94
New
29
Increased
16
Reduced
28
Closed
16

Top Buys

Rank Stock Value
1
SYT
Syngenta Ag
SYT
+$5.86M
2
BFYT
Benefytt Technologies, Inc. Class A Common Stock
BFYT
+$5.08M
3
SHOR
ShoreTel, Inc.
SHOR
+$2.1M
4
SANW
S&W Seed Co
SANW
+$1.65M
5
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
+$1.38M

Top Sells

Rank Stock Value
1
CALX icon
Calix
CALX
+$6.16M
2
DRRX
DURECT Corp
DRRX
+$3.14M
3
LSAK icon
Lesaka Technologies
LSAK
+$3.03M
4
ARAY icon
Accuray
ARAY
+$2.56M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$2.36M

Sector Composition

Rank Sector Weight
1 Healthcare 46.71%
2 Technology 20.22%
3 Communication Services 8.22%
4 Materials 7.79%
5 Financials 5.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRL icon
26
Scully Royalty
SRL
$88.9M
$1.11M 0.97%
28,020
– –
ACFN
27
DELISTED
Acorn Energy Inc
ACFN
$1.05M 0.92%
311,700
-16,000
-5% -$58.3K
STRM
28
DELISTED
Streamline Health Solutions
STRM
$998K 0.87%
13,220
-2,100
-14% -$195K
CYNI
29
DELISTED
CYAN INC COM
CYNI
$964K 0.84%
225,699
-129,000
-36% -$490K
SQNS
30
Sequans Communications SA
SQNS
$44.3M
$906K 0.79%
3,206
-3,346
-51% -$893K
HNGR
31
DELISTED
Hanger Inc.
HNGR
$882K 0.77%
26,233
+2,433
+10% +$88.1K
ARWR icon
32
Arrowhead Research
ARWR
$12.5B
$802K 0.7%
48,958
-91,900
-65% -$1.61M
NKTR icon
33
Nektar Therapeutics
NKTR
$2.55B
$728K 0.64%
+4,013
New +$794K
SAP icon
34
SAP
SAP
$255B
$668K 0.59%
+8,200
New +$650K
CPRX
35
DELISTED
Catalyst Pharmaceutical
CPRX
$638K 0.56%
+282,500
New +$591K
AVG
36
DELISTED
AVG Technologies N.V.
AVG
$637K 0.56%
30,400
+20,400
+204% +$374K
UPI
37
DELISTED
UROPLASTY INC-NEW
UPI
$627K 0.55%
172,600
-11,100
-6% -$43.4K
MNDT
38
DELISTED
Mandiant, Inc. Common Stock
MNDT
$618K 0.54%
10,000
-23,700
-70% -$1.68M
SCTL
39
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$540K 0.47%
+81,953
New +$596K
SNOA icon
40
Sonoma Pharmaceuticals
SNOA
$6.37M
$522K 0.46%
+154
New +$523K
EW icon
41
Edwards Lifesciences
EW
$51.8B
$519K 0.45%
+42,000
New +$485K
RTK
42
DELISTED
Rentech, Inc.
RTK
$512K 0.45%
26,956
+12,360
+85% +$230K
AVAV icon
43
AeroVironment
AVAV
$7.74B
$511K 0.45%
12,700
+7,500
+144% +$244K
NSPR icon
44
InspireMD
NSPR
$41.6M
– –
0
– –
TPST icon
45
Tempest Therapeutics
TPST
$17.9M
$498K 0.44%
+19
New +$539K
SNMX
46
DELISTED
Senomyx, Inc.
SNMX
$477K 0.42%
+44,700
New +$374K
KFX
47
DELISTED
KOFAX LIMITED COM STK
KFX
$466K 0.41%
+53,600
New +$423K
FPRX
48
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$438K 0.38%
+22,300
New +$379K
EGHT icon
49
8x8 Inc
EGHT
$290M
$436K 0.38%
+40,300
New +$424K
EVOK
50
DELISTED
Evoke Pharma
EVOK
$411K 0.36%
+340
New +$485K
1
2
3 4

Similar funds

SFM
Socratic Fund Management Short Hills, New Jersey $12M AUM 39.3% 1-Year Est. Return
IACGFA
IDG-Accel China Growth Fund Associates Central, Hong Kong $13.2M AUM 31.6% 1-Year Est. Return
LS
Lupo Securities Chicago, Illinois $13.3M AUM 1.59% 1-Year Est. Return
NGPI
N.G. Partners II Palo Alto, California $9.65M AUM 70.44% 1-Year Est. Return
AP
AGTC Partners Cambridge, Massachusetts $13.6M AUM 15.62% 1-Year Est. Return
GRP
Geologic Resource Partners Boston, Massachusetts $9.22M AUM 48.14% 1-Year Est. Return
NVPV
Norwest Venture Partners VIII Palo Alto, California $9.22M AUM
AC
Amiya Capital London, United Kingdom $14.3M AUM 4.61% 1-Year Est. Return

Sophrosyne Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Sophrosyne Capital held 94 positions worth $114M, up 0.01% from $114M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sophrosyne Capital withdrew a net $8.9M in Q1 2014, closing 16 positions and reducing 28 holdings. Its most notable exit was Calix, an estimated $6.16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 55% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sophrosyne Capital opened a new position in Benefytt Technologies, Inc. Class A Common Stock worth $4.65M.

  • Sophrosyne Capital's largest Q1 2014 buy was Benefytt Technologies, Inc. Class A Common Stock: 449,845 shares worth $4.65M.
  • Sophrosyne Capital added most to Syngenta Ag in Q1 2014, an estimated $5.86M increase.
  • Sophrosyne Capital's biggest Q1 2014 reduction was Lesaka Technologies, cutting an estimated $3.03M.
  • Sophrosyne Capital fully exited Calix in Q1 2014, selling an estimated $6.16M.
  • Sophrosyne Capital's ten largest holdings make up 53% of its $114M portfolio in Q1 2014.
  • Sophrosyne Capital opened 29 new positions and closed 16 in Q1 2014.
  • Sophrosyne Capital's portfolio value rose 0.01% quarter-over-quarter to $114M.

Based on Sophrosyne Capital's 13F filing for Q1 2014, filed 14 May 2014.